| Agents targeting ErbB receptors have
also been tested in conjunction with more
chemotherapeutic compounds.1-6 Trastuzumab has been paired
|with a variety of
agents for the treatment of MBC, and all have demonstrated
In the BOND trial, the combination of cetuximab/irinotecan in
irinotecan-refractory metastatic CRC induced a higher RR than
though both approaches showed activity.5
|1. Slamon DJ, Leyland-Jones B, Shak S, et al.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
|2. Seidman AD, Fornier MN, Esteva FJ, et al.
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with
analysis of efficacy by HER2 immunophenotype and gene amplification. J
Clin Oncol 2001; 19:2587-95.
|3.Esteva FJ, Valero V, Booser D, et al. Phase II study of
weekly docetaxel and trastuzumab for patients with HER-2-overexpressing
metastatic breast cancer. J Clin Oncol 2002; 20:1800-8.
|4.Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and
vinorelbine as first-line therapy for HER2-overexpressing metastatic breast
cancer: multicenter phase II trial with clinical outcomes, analysis of serum
tumor markers as predictive factors, and cardiac surveillance algorithm. J
Clin Oncol 2003; 21:2889-95.
|5.Cunningham D, Humblet Y, Siena S. Cetuximab (C225) alone or
in combination with irinotecan (CPT-11) in patients with epidermal
growth-factor receptor (EGFR)-positive, irinotecan-refractory metastatic
colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 2003; 22:252
|6.Fisher GA, Kuo T, Cho CD, et al. A phase II study of
gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic
colorectal cancer. Proc Am Soc Oncol 2004:Abstract 3514.